SIGHT SCIENCES INC
SGHTNASDAQTrading Snapshot
- Day Range
- $9.25 – $9.63
- 52-Week Range
- $3.38 – $9.71
- Volume (shares)
- 346,456
- Avg Volume (shares)
- —
- Shares Outstanding
- 55.1M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $77M
- Last Q Revenue
- $23M
- P/E Ratio
- -16.5
- P/S Ratio
- 6.1x
- EPS (TTM)
- $-0.55
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.5%
SIGHT SCIENCES INC
SGHT
StockOtter · stockotter.spaceAbout SIGHT SCIENCES INC
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventiona
Why Is Sight Sciences Stock Gaining Thursday?
Sight Sciences, Inc. (NASDAQ:SGHT) stock gained Thursday after H.C. Wainwright initiated coverage with a Buy rating and a $14 price forecast.
Sight Sciences, Inc. (NASDAQ:SGHT) Stock Has Consensus Price Target of $8.38
Shares of Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat reports. One invest
Sight Sciences: Signs Of Progress, But Plenty Of Work Remains
Sight Sciences is a cautious 'buy,' as recent reimbursement wins and product momentum support a positive outlook, offset by liquidity pressures and ongoing reimbursement and utilization challenges. SGHT's OMNI Ultra Surg
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technolo